GlassScriptPhysician profile
Alexander Michael Nelson
NPI 1003547811
$4,013.36
in general payments reported to CMS, 2019-2025
24 companies · $1,229 in 2025
The $1,229 reported for 2025 was more than what 90% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $340 · 2023: $1,857 · 2024: $588 · 2025: $1,229.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,664 · Education: $9.65.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,663.81 |
| Education | $9.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,072.72 | 2022-2025 | |
| Janssen Biotech, INC. | $729.28 | 2025 | Tremfya |
| Novo Nordisk INC | $480.47 | 2022-2024 | Wegovy, Rybelsus, Ozempic |
| Idorsia Pharmaceuticals US INC | $237.52 | 2023 | Quviviq |
| Novartis Pharmaceuticals Corporation | $203.21 | 2024-2025 | |
| Lilly USA, LLC | $200.65 | 2022-2023 | Jardiance, Mounjaro, Trulicity |
| Astrazeneca Pharmaceuticals LP | $146.37 | 2022-2024 | Farxiga, Airsupra, Breztri |
| Glaxosmithkline, LLC. | $131.83 | 2023-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Axsome Therapeutics, INC. | $122.41 | 2023 | Auvelity |
| Pfizer INC. | $116.61 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $93.55 | 2022-2024 | Trintellix |
| Amgen INC. | $86.00 | 2023-2024 | Evenity, Prolia, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $59.80 | 2023-2024 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $46.88 | 2024 | Sotyktu |
| Seqirus USA INC | $45.47 | 2023 | Flucelvax Quadrivalent, Fluad Quadrivalent |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $43.86 | 2023 | Rexulti |
| Astellas Pharma US INC | $37.67 | 2023-2025 | Veozah |
| Exact Sciences Corporation | $36.24 | 2023 | Cologuard Collection Kit |
| Currax Pharmaceuticals LLC | $29.29 | 2023 | Onzetra Xsail, Contrave |
| Corium, LLC | $23.89 | 2023 | Azstarys |
| Biohaven Pharmaceutical Holding Company LTD. | $18.06 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $17.92 | 2023 | |
| Daiichi Sankyo INC. | $17.85 | 2024 | Injectafer |
| Arcutis Biotherapeutics, INC. | $15.81 | 2025 | Zoryve |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexander Nelson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.